Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 362.96% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 825.93% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 270.37% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 733.33% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 455.56% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 640.74% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 362.96% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 38.89% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 1288.89% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 1381.48% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 1103.7% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 1288.89% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 1751.85% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 362.96% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 1659.26% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 1937.04% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 1381.48% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 2214.81% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 1751.85% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 1937.04% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 1196.3% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 918.52% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 918.52% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 362.96% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 2023年08月11日 | 825.93% | 韋德布什 | $16→$10 | 維護 | 跑贏大盤 |
| 2023年08月10日 | 270.37% | 富國銀行 | $5→$4 | 維護 | 超重 |
| 08/09/2023 | 733.33% | 巴克萊 | $11→$9 | 維護 | 超重 |
| 08/09/2023 | 455.56% | 加拿大皇家銀行資本 | $8→$6 | 維護 | 跑贏大盤 |
| 2023年05月10日 | 640.74% | Truist證券 | $16→$8 | 維護 | 買 |
| 05/01/2023 | 362.96% | HC Wainwright公司 | $15→$5 | 維護 | 買 |
| 04/28/2023 | 38.89% | B of A證券 | $5→$1.5 | 評級下調 | 中性→表現不佳 |
| 03/03/2023 | 1288.89% | HC Wainwright公司 | $25→$15 | 維護 | 買 |
| 02/27/2023 | 1381.48% | 韋德布什 | →$16 | 升級 | 中性→表現優異 |
| 02/23/2023 | 1103.7% | 加拿大皇家銀行資本 | $22→$13 | 維護 | 跑贏大盤 |
| 01/04/2023 | 1288.89% | 富國銀行 | $20→$15 | 維護 | 超重 |
| 11/07/2022 | 1751.85% | 富國銀行 | $22→$20 | 維護 | 超重 |
| 2022/06/13 | 362.96% | 韋德布什 | →$5 | 假設 | →中性 |
| 04/05/2022 | 1659.26% | Truist證券 | $23→$19 | 維護 | 買 |
| 05/04/2021 | 1937.04% | 加拿大皇家銀行資本 | →$22 | 開始承保 | →跑贏大盤 |
| 01/06/2021 | 1381.48% | Stifel | →$16 | 開始承保 | →保留 |
| 12/16/2020 | 2214.81% | HC Wainwright公司 | →$25 | 假設 | →購買 |
| 09/08/2020 | 1751.85% | B of A證券 | →$20 | 恢復 | →購買 |
| 07/07/2020 | 1937.04% | SunTrust Robinson Humphrey | →$22 | 開始承保 | →購買 |
| 06/22/2020 | 1196.3% | HC Wainwright公司 | $16→$14 | 維護 | 買 |
| 2018年11月14日 | 918.52% | 摩根大通 | $35→$11 | 維護 | 中性 |
| 2018年11月14日 | 918.52% | 摩根大通 | $35→$11 | 評級下調 | 超重→中性 |
| 2018/09/11 | - | 古根海姆 | 評級下調 | 購買→中性 |
What is the target price for Sangamo Therapeutics (SGMO)?
Sangamo治療公司(SGMO)的目標價格是多少？
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 362.96% upside). 13 analyst firms have reported ratings in the last year.
桑加莫治療公司(納斯達克代碼：SGMO)的最新目標價是由HC Wainwright&Co.於2023年8月14日報道的。這家分析公司將目標價定為5美元，預計新交所股價將在12個月內上漲(漲幅可能為362.96%)。過去一年，有13家分析公司公佈了評級。
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
Sangamo治療公司(SGMO)的最新分析師評級是多少？
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating.
桑加莫治療公司(納斯達克代碼：SGMO)的最新分析師評級由HC Wainwright&Co.提供，Sangamo治療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Sangamo治療公司(SGMO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Sangamo治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sangamo治療公司的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候提供。
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
分析師對Sangamo Treeutics(SGMO)的評級正確嗎？
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a reiterated with a price target of $0.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $1.08, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sangamo治療(SGMO)評級被重申，目標價在0.00美元至5.00美元之間。Sangamo治療公司(SGMO)目前的交易價格為1.08美元，在分析師的預測範圍內。